Whilst some studies have suggested that specific cut-off levels of CK-18 can reliably detect NASH in a cohort of NAFLD subjects [6]–[10], others have not shown such promising results [11]–[13]. This evidence concerns the gene KRT18 and metabolic dysfunction-associated steatotic liver disease.